UBS raised the firm’s price target on Johnson & Johnson to $190 from $180 and keeps a Buy rating on the shares. Johnson & Johnson is well-positioned to deliver upside into the second half following the strong beat and raise quarter, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $167 from $164 at Guggenheim
- Johnson & Johnson granted FDA Priority Review for TAR-200 NDA
- Johnson & Johnson price target raised to $175 from $161 at BofA
- Johnson & Johnson price target raised to $172 from $159 at Bernstein
- Johnson & Johnson price target raised to $176 from $165 at Barclays